Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer

On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.

---